During the corresponding time, Personalis Inc recorded a revenue increase by 29.96 % year on year, sequentially revenue grew by 44.5 %. While revenue at the Personalis Inc 's corporate clients
Personalis Inc's Comment on Sales, Marketing and Customers
The company serves customers including the U.S. Department of Veterans Affairs' Million Veteran Program (VA MVP), ModernaTX, Inc., Merck & Co., Inc., and other collaboration partners. It has a Commercialization and Reference Laboratory Agreement with Tempus AI, Inc. The company focuses on sales, marketing, and commercialization efforts to introduce its testing services to new customers and expand its market presence.
In a pioneering leap for precision oncology, Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics, has announced a promising collaboration with a renowned team from Yale Cancer Center. Together, they are embarking on an ambitious clinical trial aimed at demonstrating the transformative potential of circulating tumor DNA (ctDNA) in guiding breast cancer treatment decisions, particularly in hormone receptor-positive, HER2-negative breast cancers prone to late recurrence.This single-arm Phase II trial, aptly named CATE (Circulating Tumor DNA-Guided Adjuvant Therapy with Elacestrant), endeavors to refine and enhance treatment strategies for breast cancer patients identified at heightened risk for recur...
In a significant move within the healthcare landscape, Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) have announced an expansion of their collaboration aimed at bringing ultra-sensitive minimal residual disease (MRD) testing to the market. This partnership, which was formalized in November 2023, seeks to deliver innovative testing solutions for breast and lung cancers, promising to enhance patient outcomes and streamline the path to diagnosis and treatment.The collaboration was officially launched at the recent American Society of Clinical Oncology (ASCO) meeting, where both companies showcased the potential benefits of their ultra-sensitive tumor-informed MRD product. With Tempus serving...
Tempus and Personalis Launch Commercialization of Advanced Cancer MRD Testing with NeXT Personal Dx AssayFREMONT, Calif. Personalis, Inc. (Nasdaq: PSNL), a pioneering force in advanced genomics for precision oncology, has announced a significant collaborative venture with Tempus, a prominent technology company advancing the connection between molecular data and real-world evidence for better healthcare outcomes. This partnership heralds the commencement of concerted commercialization efforts surrounding Personalis revolutionary liquid biopsy assay, NeXT Personal, which is designed to detect minimal residual disease (MRD) and potential recurrence of cancer in patients.NeXT Personal is an ultra-sensitive, ...
Personalis Inc’s Comment on Sales, Marketing and Customers
The company serves customers including the U.S. Department of Veterans Affairs' Million Veteran Program (VA MVP), ModernaTX, Inc., Merck & Co., Inc., and other collaboration partners. It has a Commercialization and Reference Laboratory Agreement with Tempus AI, Inc. The company focuses on sales, marketing, and commercialization efforts to introduce its testing services to new customers and expand its market presence.
Sources:
Personalis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Personalis Inc’s corporate clients.
For your research, we’ve provided 9 tables on Personalis Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
